Main Line biotech firm raises $40M in Series A round to advance new high blood pressure treatment

Mineralys Therapeutics, a Radnor-based biopharmaceutical startup, said Tuesday it has raised $40 million through a private stock sale. Founded in 2020 by Tokyo venture capital firm Catalys Pacific, Mineralys is focused on developing new treatments for high blood pressure — also known as hypertension. The company's Series A funding round was led by HBM Healthcare Investments of Switzerland and Samsara BioCapital of Palo Alto, C alifornia. Catalys Pacific and Adam Street Partners also participated…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news